Tizanac 2 mg (Tablet)

Unit Price: ৳ 5.00 (30's pack: ৳ 150.00)

Medicine Details

Category	Details
Generic	Tizanidine hydrochloride
Company	Globe pharmaceuticals ltd

Treatment of painful muscle spasms
Treatment of spasticity due to neurological disorders
Associated with static and functional disorders of the spine (cervical and lumbar syndromes)
Following surgery, e.g. for herniated intervertebral disc or osteoarthritis of the hip
Multiple sclerosis
Chronic myelopathy
Degenerative spinal cord diseases
Cerebrovascular accidents
Cerebral palsy

Centrally acting skeletal muscle relaxant
Principal site of action is the spinal cord
Inhibits the release of excitatory amino acids
Polysynaptic signal transmission at spinal interneuron level is inhibited
Moderate central analgesic effect
Effective in both acute painful muscle spasms and chronic spasticity of spinal and cerebral origin
Reduces resistance to passive movements
Alleviates spasms and clonus
May improve voluntary strength
Antispastic activity measured by the Ashworth score and pendulum test
Adverse effects related to plasma tizanidine concentrations

Narrow therapeutic index
High inter-patient variability in tizanidine plasma concentrations
Low starting dose of 2 mg three times daily
Usual dose for relief of painful muscle spasms: 2 to 4 mg three times daily
Extra dose of 2 or 4 mg may be taken in severe cases
Initial daily dose for spasticity due to neurological disorders should not exceed 6 mg
Optimum therapeutic response generally achieved with a daily dose of between 12 and 24 mg
Pediatrics patients: Limited experience, not recommended
Geriatric patients: Limited experience, start at lowest dose
Renal impairment: Start treatment at 2 mg once daily
Hepatic impairment: Contraindicated in severe cases, caution in moderate cases
Discontinuation: Dosage should be slowly down titrated to avoid rebound hypertension and tachycardia

Concomitant administration of drugs known to inhibit the activity of CYP1A2 may increase plasma levels of tizanidine
Concomitant administration of drugs known to induce the activity of CYP1A2 may decrease plasma levels of tizanidine
Contraindicated with fluvoxamine or ciprofloxacin
Concomitant use not recommended with other CYP1A2 inhibitors
Caution with drugs known to prolong the QT interval
Concomitant use with antihypertensives may occasionally cause hypotension
Concomitant administration with rifampicin results in decrease in tizanidine concentrations
Cigarette smoke decreases tizanidine systemic exposure
Alcohol consumption should be minimized or avoided
Caution when given with sedatives, hypnotics, antihistamines, and other alpha-2 adrenergic agonists

Known hypersensitivity to tizanidine or to any of the excipients
Severely impaired hepatic function
Concomitant use with strong inhibitors of CYP1A2 such as fluvoxamine or ciprofloxacin

Limited experience in pregnant women, not recommended unless benefit outweighs risk
Animal studies showed some effects on gestation and pup loss
Tizanidine excreted in rat milk
Pregnancy testing recommended for sexually-active females of reproductive potential
Use effective contraception during treatment and for 1 day after stopping treatment
No impairment of fertility observed in animal studies

Caution with moderate CYP1A2 inhibitors
Hypotension may occur
Risk of withdrawal syndrome if abruptly stopped
Liver function tests recommended in high dose cases
Increased systemic exposure in patients with renal impairment
Hypersensitivity reactions reported
Patients experiencing somnolence, dizziness, or hypotension should refrain from activities requiring alertness